# Valsartan

Drug · id `cardio:valsartan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Diovan

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease; Heart failure  

## In plain language

Valsartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for Diovan tablets (valsartan), lists three uses: treating high blood pressure in adults and children 1 year and older, reducing hospitalization for heart failure (NYHA class II-IV) in adults, and reducing cardiovascular deaths in clinically stable adults with left ventricular failure or dysfunction after a myocardial infarction. Diovan is the brand name on the label read.

## Technical summary

RxNorm ingredient 69749; UNII 80M03YXJ7I. UNII 80M03YXJ7I is the UNII of the substance as the label names it. MeSH descriptor D000068756 is Valsartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Novartis Pharmaceuticals Corporation label for Diovan (valsartan) tablets, application NDA021283, effective 2026-08-11 in openFDA; Drugs@FDA lists the application's sponsor as NOVARTIS. Other valsartan labels, the Diovan HCT combination label and fixed-dose combination labels with other substances were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Adults for whom the US label of valsartan (Diovan) lists an indication: hypertension, NYHA class II-IV heart failure, left ventricular failure or dysfunction after myocardial infarction

Recipient: Adult; Population: Adult patients described in the indications section of the label. The hypertension sentence also names children, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passages read state; Follow-up: Not applicable (label statement)

### The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults; and for the reduction of cardiovascular mortality in clinically stable adults with left ventricular failure or left ventricular dysfunction following myocardial infarction.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients described in the indications section of the label. The hypertension sentence also names children, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passages read state; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective\_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%225ddba454-f3e6-43c2-a7a6-58365d297213%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:18:43Z. Source state: Current. Version fingerprint: 688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective\_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%225ddba454-f3e6-43c2-a7a6-58365d297213%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:18:43Z. Source state: Current. Version fingerprint: 688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d.
     How it applies: Effective date of the label text read, 20260811.
  3. Background: openFDA Drugs@FDA record for application NDA021283 (DIOVAN, sponsor NOVARTIS): product and sponsor (Regulator, edition The openFDA Drugs@FDA record for application NDA021283, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021283%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-11-09T13:20:31Z. Source state: Current. Version fingerprint: a78049a0e3c8f2cb62336a0d03a25f1f483fb5af1df4497ffbd39f3710ee44ee.
     How it applies: Drugs@FDA product listing for application NDA021283, which confirms the product the label belongs to.

## Context: Children for whom the US label of valsartan (Diovan) lists hypertension as an indication: children 1 year and older

Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children 1 year and older; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure, in children 1 year and older.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children 1 year and older; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective\_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%225ddba454-f3e6-43c2-a7a6-58365d297213%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:18:43Z. Source state: Current. Version fingerprint: 688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d.
     How it applies: The label sentence that names children in the hypertension indication, quoted in the research quote table.
  2. Background: openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective\_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%225ddba454-f3e6-43c2-a7a6-58365d297213%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:18:43Z. Source state: Current. Version fingerprint: 688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d.
     How it applies: Effective date of the label text read, 20260811.

## Connected pages

- Valsartan is an ARB (FDA established pharmacologic class in RxClass): Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-valsartan-label-indications` and its context]
- FDA label lists NYHA class II to IV heart failure, to reduce hospitalization for heart failure in adults, as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-valsartan-label-indications` and its context]
- FDA label lists reduction of cardiovascular mortality after myocardial infarction in clinically stable adults with left ventricular failure or dysfunction as an indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-valsartan-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 9 registry products
- 24 registry trials

## Provenance

Content hash: fe2b710435b27ded9faa8be25db3ebef6b5fdbf8145db28011671a152b3fa124
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
